Prazoto IV injection2018-12-08T09:04:12+00:00
Prazoto-IV-injection criticare product

Prazoto IV contains pantoprazole. It is a drug belonging to a class known as proton pump inhibitors. It helps in reduction of acid in stomach. It produces immediate relief in heart burns. It is potent inhibitor in gastric acid reduction.

  • Short term treatment for erosive esophagitis associated with GERD
  • It is indicated for the maintenance of healing of erosive esophagitis
  • Reduction in the symptoms of heartburn in day and night time
  • In hypersecretory symptoms
  • Zollinger-Ellison syndrome
  • Short term treatment in patients of five year and above
  • GERD

Once daily by intravenous infusion for 7 to 10 days.

It produces its action by formation of covalent bond to two sides of the (H+,K+)- ATPase enzyme system on the secretory surface of the gastric parietal cells is the final step in gastric acid production which is inhibited by pantoprazole.

Absorption:

 It is well absorbed in body. It undergoes first pass metabolism with bioavailability of 77% .

Distribution:

The drug protein binding is 98%. The metabolism of the drug through cytochrome P450 (CYP) in liver. The CYP2C19 causes demethylation and subsequent sulfation. The metabolism of the drug also includes oxidation by CYP3A4.

Excretion:

Elimination of the drug through urine is about 71% and 18% through feces by biliary excretion.

  • Patient with hypersensitivity reaction
  • Anaphylaxis
  • Anaphylactic shock
  • Angioedema
  • Bronchspasm
  • Acute intestinal nephritis
  • Urticaria
  • Long term use causes acute interstitial nephritis
  • Long treatment with acid suppressing drug causes malabsorption
  • Patient with high risk of Clostridium difficileassociated diarrhea treating with acid suppressing drug
  • Can increase the risk of osteoporosis
  • Should not be prescribed for long term treatment because it can even cause gastrointestinal tumors.